Please use this identifier to cite or link to this item:
http://dspace.univ-bouira.dz:8080/jspui/handle/123456789/14594Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Ait-Tahar, Kamal | - |
| dc.date.accessioned | 2023-04-16T12:03:48Z | - |
| dc.date.available | 2023-04-16T12:03:48Z | - |
| dc.date.issued | 201 | - |
| dc.identifier.citation | blood journal | en_US |
| dc.identifier.uri | http://dspace.univ-bouira.dz:8080/jspui/handle/123456789/14594 | - |
| dc.description.abstract | Immunotherapy is an important treatment option in multiple myeloma (MM), with allotransplantation demonstrating an inducible graft-versusmyeloma effect.1 This could be potentiated by vaccination, first requiring knowledge of tumor-associated antigens. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Université de BOUIRA جامعة البويرة | en_US |
| dc.title | PASD1 is a potential multiple myeloma–associated antigen | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Articles | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 3953.full.pdf | PASD1 is a potential multiple myeloma–associated antigen | 460,16 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.